Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

This article evaluates a patent application from Solvay Pharmaceuticals, which claims spiro azepane-oxazolidinones as novel blockers of the voltage-gated potassium channel Kv1.3 for the treatment of diabetes, psoriasis, obesity, transplant rejection and T-cell mediated autoimmune diseases such as rheumatoid arthritis and MS. The patent describes a new chemotype of Kv1.3 blockers and thus illustrates the growing interest of the pharmaceutical industry in Kv1.3 as a target of immunosuppression and metabolic disorders. This article briefly summarizes the chemistry and biological data provided in the patent and then compares the new compounds to Kv1.3 blockers previously disclosed by both academia and pharmaceutical companies.

Original languageEnglish (US)
Pages (from-to)1759-1765
Number of pages7
JournalExpert Opinion on Therapeutic Patents
Volume20
Issue number12
DOIs
StatePublished - Dec 2010

Fingerprint

Kv1.3 Potassium Channel
Potassium Channel Blockers
Oxazolidinones
Voltage-Gated Potassium Channels
Drug Industry
Graft Rejection
Psoriasis
Pharmaceutical Preparations
Immunosuppression
Autoimmune Diseases
Rheumatoid Arthritis
Obesity
T-Lymphocytes
Therapeutics

Keywords

  • diabetes
  • immunosuppression
  • Kv1.3
  • MS
  • potassium channel
  • spiro azepane-oxazolidinones

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers : WO2010066840. / Wulff, Heike.

In: Expert Opinion on Therapeutic Patents, Vol. 20, No. 12, 12.2010, p. 1759-1765.

Research output: Contribution to journalArticle

@article{a587e25589fc4a69b9f9f2bd78b53dc7,
title = "Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840",
abstract = "This article evaluates a patent application from Solvay Pharmaceuticals, which claims spiro azepane-oxazolidinones as novel blockers of the voltage-gated potassium channel Kv1.3 for the treatment of diabetes, psoriasis, obesity, transplant rejection and T-cell mediated autoimmune diseases such as rheumatoid arthritis and MS. The patent describes a new chemotype of Kv1.3 blockers and thus illustrates the growing interest of the pharmaceutical industry in Kv1.3 as a target of immunosuppression and metabolic disorders. This article briefly summarizes the chemistry and biological data provided in the patent and then compares the new compounds to Kv1.3 blockers previously disclosed by both academia and pharmaceutical companies.",
keywords = "diabetes, immunosuppression, Kv1.3, MS, potassium channel, spiro azepane-oxazolidinones",
author = "Heike Wulff",
year = "2010",
month = "12",
doi = "10.1517/13543776.2010.528392",
language = "English (US)",
volume = "20",
pages = "1759--1765",
journal = "Expert Opinion on Therapeutic Patents",
issn = "1354-3776",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers

T2 - WO2010066840

AU - Wulff, Heike

PY - 2010/12

Y1 - 2010/12

N2 - This article evaluates a patent application from Solvay Pharmaceuticals, which claims spiro azepane-oxazolidinones as novel blockers of the voltage-gated potassium channel Kv1.3 for the treatment of diabetes, psoriasis, obesity, transplant rejection and T-cell mediated autoimmune diseases such as rheumatoid arthritis and MS. The patent describes a new chemotype of Kv1.3 blockers and thus illustrates the growing interest of the pharmaceutical industry in Kv1.3 as a target of immunosuppression and metabolic disorders. This article briefly summarizes the chemistry and biological data provided in the patent and then compares the new compounds to Kv1.3 blockers previously disclosed by both academia and pharmaceutical companies.

AB - This article evaluates a patent application from Solvay Pharmaceuticals, which claims spiro azepane-oxazolidinones as novel blockers of the voltage-gated potassium channel Kv1.3 for the treatment of diabetes, psoriasis, obesity, transplant rejection and T-cell mediated autoimmune diseases such as rheumatoid arthritis and MS. The patent describes a new chemotype of Kv1.3 blockers and thus illustrates the growing interest of the pharmaceutical industry in Kv1.3 as a target of immunosuppression and metabolic disorders. This article briefly summarizes the chemistry and biological data provided in the patent and then compares the new compounds to Kv1.3 blockers previously disclosed by both academia and pharmaceutical companies.

KW - diabetes

KW - immunosuppression

KW - Kv1.3

KW - MS

KW - potassium channel

KW - spiro azepane-oxazolidinones

UR - http://www.scopus.com/inward/record.url?scp=78649285270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649285270&partnerID=8YFLogxK

U2 - 10.1517/13543776.2010.528392

DO - 10.1517/13543776.2010.528392

M3 - Article

C2 - 20954790

AN - SCOPUS:78649285270

VL - 20

SP - 1759

EP - 1765

JO - Expert Opinion on Therapeutic Patents

JF - Expert Opinion on Therapeutic Patents

SN - 1354-3776

IS - 12

ER -